Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

NCT07072351 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma
Hypofractionated Radiotherapy
Immunotherapy
Chemotherapy

Interventions

RADIATION: hypofractionated radiotherapy
DRUG: SOX Chemotherapy
DRUG: PD-1 inhibitor

Sponsor

West China Hospital